IPO + Biotech = Uncertainty

After a long famine, and buoyed by the stock market's overall health over the past 18 months, investors are once again feasting on initial public offerings (IPOs). Prominent among them are biotech firms. The news is good for the cash-starved biotech companies, since they finally have a place to raise money. But the news is not as good for IPO investors, who are getting uncertain returns in the post-IPO aftermarket."Although the general markets have been choppy all year and are likely to remain s


Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

After a long famine, and buoyed by the stock market's overall health over the past 18 months, investors are once again feasting on initial public offerings (IPOs). Prominent among them are biotech firms. The news is good for the cash-starved biotech companies, since they finally have a place to raise money. But the news is not as good for IPO investors, who are getting uncertain returns in the post-IPO aftermarket.

"Although the general markets have been choppy all year and are likely to remain so, the biotech industry has raised $13 billion already in 2004 and close to $29 billion" since this time last year, says Steven Burrill, CEO of Burrill & Company, a San Francisco-based investment bank that specializes in the biotech and life-sciences industries. "Since the IPO window opened in October 2003, 25 new biotech companies have entered the [public] market" in the United States, says Burrill, and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Discover a serum-free way to produce dendritic cells and macrophages for cell therapy applications.

Optimizing In Vitro Production of Monocyte-Derived Dendritic Cells and Macrophages

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with Lipid Nanoparticles

Thermo Fisher Logo